While 23andMe and FDA reached loggerheads over the company's submission of analytical validity data, the larger story is how their negotiations could set precedents that shape the future of personal genetics.
Celgene is outsourcing its big play in cancer stem cells in a six-program deal that could mean OncoMed may never need to raise more capital.
Merck Serono's TocopheRx spinout provides a glimpse into the pharma's strategy for advancing early stage assets in the fertility market.
EMERGING COMPANY PROFILE
ClinMet is using metabolomics to aid product discovery by finding disease-specific metabolite panels that monitor drug efficacy and provide insights about the mechanism of action of new products.
Industry attorneys warn EMA's draft policy on data transparency may have the unintended consequence of jeopardizing data exclusivity outside Europe.
The ability to create a consolidated cancer immunotherapy powerhouse with a host of clinical programs led Arch and Alaska Permanent Fund to commit $120 million in the largest series A round of the decade.
A task force of bankers, investors and industry players is waiting for SEC to respond to the group's recommendations for improving liquidity and access to capital for small cap companies.
Celgene, Lilly sweeten VC pot for NYC. Editas gets crisp money. MS Ventures plants more seeds in Israel. Sofinnova not blind to Pixium's opportunity. Also: Wetherell-Burrill; AcelRx; Auxilium; Immunocellular; Lexicon; Merrimack; Orexigen; Puma; Receptos; Oncolys; TWi; Xencor, et al.